Results: Additional findings: 14.1% (9 mg) and 12.0% (12 mg) achieved complete freedom from knee pain Significant reductions in cardiovascular risk markers 14.0 mmHg reduction in systolic blood pressure at highest dose Reductions in non-HDL cholesterol, triglycerides, and inflammatory markers Liver fat reduction (MASLD substudy) A separate analysis looked at retatrutide's effect on metabolic dysfunction-associated steatotic liver disease (formerly NAFLD): Liver fat reduction at 24 weeks: Achievement of normal liver fat ( 20%) Patients with multiple metabolic conditions Who should avoid it Contraindications based on trial exclusions: Personal or family history of medullary thyroid carcinoma Multiple endocrine neoplasia syndrome type 2 Pregnancy or planning pregnancy Severe kidney disease History of pancreatitis Active gallbladder disease For women-specific considerations, see our peptides for menopause guide

These predispositions do not predict exact medication response but may help providers understand whether GLP-1 agonists align with a patient's genetic metabolic profile
Every injection day, reference the screenshot instead of recalculating
But let's pause before you celebrate: Despite this encouraging dip, access disparities and long-term efficacy remain critical issues
Plain water, herbal tea, and sugar-free electrolyte drinks are safer choices
Thus, GLP-1R is thought to be a key component of the incretin effectinsulin secretion in response to oral glucose intake [27]